Evaluating in vivo PARP-1 expression with 18F-FluorThanatrace positron emission tomography (PET/CT) in Patients with Pheochromocytoma and Paraganglioma
Recruiting
18-99 years
All
Phase
1
30 participants needed
1 Location
Brief description of study
The purpose of this study is to learn if a special type of imaging drug, called a “radioactive tracer” can help doctors see sites of pheochromocytoma or paraganglioma more clearly when used with a procedure called Positron Emission Tomography/Computed Tomography (PET/CT).”
Eligible participants will complete the following research procedures:
• Up to 2 18F-FTT PET/CT scans: before starting a new treatment for pheochromocytoma or paraganglioma and 1-21 days after start of treatment (The second scan is OPTIONAL).
• Optional research collection of tissue from a surgical specimen or clinical biopsy (if applicable).
Participants who agree to the scan after treatment, may be in the study for up to 6 weeks. The active part of participation during this time will only include PET/CT scan visits. Participants will be asked for permission to store and use data related to your participation in this study for future use.
Participants will be compensated up to $150.00 per FTT PET/CT scan for participation in the study, for a potential total of $300.00 if they are undergoing two scans.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Pheochromocytoma and Paraganglioma
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
18 Sep 2024.
Study ID: 851463
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting